Safety and efficacy of off-label bulevirtide monotherapy in patients with HDV with decompensated Child-B cirrhosis—A real-world case series
Christopher Dietz-Fricke(Medizinische Hochschule Hannover), Pietro Lampertico(University of Milan), Florian P. Reiter(LMU Klinikum), R. Soffredini(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Benjamin Maasoumy(Medizinische Hochschule Hannover), Stefan Zeuzem(Goethe University Frankfurt), Andreas Geier(Universitätsklinikum Würzburg), Juliana Gödiker(University Hospital Münster), Julia M. Grottenthaler(University of Tübingen), Johannes Wiegand(Charité - Universitätsmedizin Berlin), Thomas Reiberger(Harvard University), Mathias Jachs(Medical University of Vienna), Elisabetta Degasperi(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Katja Deterding(Medizinische Hochschule Hannover), Christoph P. Berg(University of Tübingen), Toni Herta(Charité - Universitätsmedizin Berlin), Bernhard Schlevogt(University Hospital Münster), Heiner Wedemeyer(Medizinische Hochschule Hannover), Kathrin Sprinzl(Goethe University Frankfurt)
Cited by 36
Related Papers
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2019|1.2k
ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
|New England Journal of Medicine|2014|877
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
|Journal of Hepatology|2016|817
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection
|New England Journal of Medicine|2017|565
High rates of 30-day mortality in patients with cirrhosis and COVID-19
|Journal of Hepatology|2020|392